AstraZeneca shores up its Tagrisso defences
The Hutchmed-originated savolitinib moves towards its first US approval.
Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
Here comes another PD-1/VEGF bispecific
OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.
